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The International Agency for Research on
Cancer (IARC) Monographs Programme
identiﬁes chemicals, drugs, mixtures,
occupational exposures, lifestyles and per-
sonal habits, and physical and biological
agents that cause cancer in humans and
has evaluated about 1000 agents since
1971. Monographs are written by ad hoc
Working Groups (WGs) of international
scientiﬁc experts over a period of about
12 months ending in an eight-day
meeting. The WG evaluates all of the
publicly available scientiﬁc information on
each substance and, through a transparent
and rigorous process,1 decides on the
degree to which the scientiﬁc evidence
supports that substance’s potential to
cause or not cause cancer in humans.
For Monograph 112,2 17 expert scien-
tists evaluated the carcinogenic hazard for
four insecticides and the herbicide glypho-
sate.3 The WG concluded that the data
for glyphosate meet the criteria for classi-
ﬁcation as a probable human carcinogen.
The European Food Safety Authority
(EFSA) is the primary agency of the
European Union for risk assessments
regarding food safety. In October 2015,
EFSA reported4 on their evaluation of the
Renewal Assessment Report5 (RAR) for
glyphosate that was prepared by the
Rapporteur Member State, the German
Federal Institute for Risk Assessment
(BfR). EFSA concluded that ‘glyphosate is
unlikely to pose a carcinogenic hazard to
humans and the evidence does not
support classiﬁcation with regard to its
carcinogenic potential’. Addendum 1 (the
BfR Addendum) of the RAR5 discusses the
scientiﬁc rationale for differing from the
IARC WG conclusion.
Serious ﬂaws in the scientiﬁc evaluation
in the RAR incorrectly characterise the
potential for a carcinogenic hazard from
exposure to glyphosate. Since the RAR is
the basis for the European Food Safety
Agency (EFSA) conclusion,4 it is critical
that these shortcomings are corrected.
THE HUMAN EVIDENCE
EFSA concluded ‘that there is very limited
evidence for an association between
glyphosate-based formulations and
non-Hodgkin lymphoma (NHL), overall
inconclusive for a causal or clear associa-
tive relationship between glyphosate and
cancer in human studies’. The BfR
Addendum (p. ii) to the EFSA report
explains that ‘no consistent positive asso-
ciation was observed’ and ‘the most
powerful study showed no effect’. The
IARC WG concluded there is limited evi-
dence of carcinogenicity in humans which
means “A positive association has been
observed between exposure to the agent
and cancer for which a causal interpret-
ation is considered by the Working Group
to be credible, but chance, bias or con-
founding could not be ruled out with rea-
sonable conﬁdence.”1
The ﬁnding of limited evidence by the
IARC WG was for NHL, based on high-
quality case–control studies, which are
particularly valuable for determining the
carcinogenicity of an agent because their
design facilitates exposure assessment and
reduces the potential for certain biases.
The Agricultural Health Study6 (AHS)
was the only cohort study available pro-
viding information on the carcinogenicity
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of glyphosate. The study had a null
ﬁnding for NHL (RR 1.1, 0.7–1.9) with
no apparent exposure–response relation-
ship in the results. Despite potential
advantages of cohort versus case–control
studies, the AHS had only 92 NHL cases
in the unadjusted analysis as compared to
650 cases in a pooled case–control ana-
lysis from the USA.7 In addition, the
median follow-up time in the AHS was
6.7 years, which is unlikely to be long
enough to account for cancer latency.8
The RAR classiﬁed all of the case–
control studies as ‘not reliable,’ because,
for example, information on glyphosate
exposure, smoking status and/or previous
diseases had not been assessed. In most
cases, this is contrary to what is actually
described in the publications.
Well-designed case–control studies are
recognised as strong evidence and rou-
tinely relied on for hazard evaluations.9 10
The IARC WG carefully and thoroughly
evaluated all available epidemiology data,
considering the strengths and weaknesses
of each study. This is key to determining
that the positive associations seen in the
case–control studies are a reliable indica-
tion of an association and not simply due
to chance or methodological ﬂaws. To
provide a reasonable interpretation of the
ﬁndings, an evaluation needs to properly
weight studies according to quality rather
than simply count the number of positives
and negatives. The two meta-analyses
cited in the IARC Monograph11 are excel-
lent examples of objective evaluations and
show a consistent positive association
between glyphosate and NHL.
The ﬁnal conclusion5 (Addendum 1,
p.21) that “there was no unequivocal evi-
dence for a clear and strong association of
NHL with glyphosate” is misleading.
IARC, like many other groups, uses three
levels of evidence for human cancer data.1
Sufﬁcient evidence means ‘that a causal
relationship has been established’ between
glyphosate and NHL. BfR’s conclusion is
equivalent to deciding that there is not
sufﬁcient evidence. Legitimate public
health concerns arise when ‘causality is
credible’, that is, when there is limited evi-
dence of carcinogenicity.
EVIDENCE FROM ANIMAL
CARCINOGENICITY STUDIES
EFSA concluded ‘No evidence of carcino-
genicity was conﬁrmed by the majority of
the experts (with the exception of one
minority view) in either rats or mice due
to a lack of statistical signiﬁcance in pair-
wise comparison tests, lack of consistency
in multiple animal studies and slightly
increased incidences only at dose levels at
or above the limit dose/maximum toler-
ated dose (MTD), lack of preneoplastic
lesions and/or being within historical
control range’. The IARC WG review
found a signiﬁcant positive trend for renal
tumours in male CD-1 mice,12 a rare
tumour, although no comparisons of any
individual exposure group to the control
group were statistically signiﬁcant. The
WG also identiﬁed a signiﬁcant positive
trend for hemangiosarcoma in male CD-1
mice,13 again with no individual exposure
group signiﬁcantly different from con-
trols. Finally, the WG also saw a signiﬁ-
cant increase in the incidence of
pancreatic islet cell adenomas in two
studies in male Sprague-Dawley rats.14–16
In one of these rat studies, thyroid gland
adenomas in females and liver adenomas
in males were also increased. By the IARC
review criteria,1 this constitutes sufﬁcient
evidence in animals.
The IARC WG reached this conclusion
using data that were publicly available in
sufﬁcient detail for independent scientiﬁc
evaluation (a requirement of the IARC
Preamble1). On the basis of the BfR
Addendum, it seems there were three add-
itional mouse studies and two additional
rat studies that were unpublished and
available to EFSA. Two of the additional
studies were reported to have a signiﬁcant
trend for renal tumours, one in CD-1 mice
(Sugimoto. 18-Month Oral Oncogenicity
Study in Mice. Unpublished, designated
ASB2012–11493 in RAR. 1997), and one
in Swiss-Webster mice (Unknown. A
chronic feeding study of glyphosate
(roundup technical) in mice. Unpublished,
designated ABS2012–11491 in RAR.
2001). One of these studies (Sugimoto.
Unpublished, 1997) also reported a signiﬁ-
cant trend for hemangiosarcoma. The
RAR also reported two studies in CD-1
mice showing signiﬁcant trends for malig-
nant lymphoma (Sugimoto. Unpublished,
1997; Unknown. Glyphosate Technical:
Dietary Carcinogencity Study in
the Mouse. Unpublished, designated
ABS2012–11492 in RAR. 2009).
The RAR dismissed the observed trends
in tumour incidence because there are no
individual treatment groups that are sig-
niﬁcantly different from controls and
because the maximum observed response
is reportedly within the range of the his-
torical control data (Table 5.3–1, p.90).
Care must be taken in using historical
control data to evaluate animal carcino-
genicity data. In virtually all guide-
lines,1 17 18 scientiﬁc reports19 and
publications20–23 on this issue, the recom-
mended ﬁrst choice is the use of concur-
rent controls and trend tests, even in the
EC regulations cited in the RAR18 (see
p.375). Trend tests are more powerful
than pairwise comparisons, particularly
for rare tumours where data are sparse.
Historical control data should be from
studies in the same time frame, for the
same animal strain, preferably from the
same laboratory or the same supplier and
preferably reviewed by the same patholo-
gist.17 18 While the EFSA ﬁnal peer
review4 mentions the use of historical
control data from the original laboratory,
no speciﬁcs are provided and the only
referenced historical control data24 are in
the BfR addendum.5 One of the mouse
studies12 was clearly done before this his-
torical control database was developed,
one study (Sugimoto. Unpublished, 1997)
used Crj:CD-1 mice rather than Crl:CD-1
mice, and one study13 did not specify the
substrain and was reported in 1993 (prob-
ably started prior to 1988). Hence, only a
single study (Unknown. Unpublished,
2009) used the same mouse strain as the
cited historical controls, but was reported
more than 10 years after the historical
control data set was developed.
The RAR dismissed the slightly
increased tumour incidences in the studies
considered because they occurred “only at
dose levels at or above the limit dose/
maximum tolerated dose (MTD)”, and
because there was a lack of preneoplastic
lesions. Exceeding the MTD is demon-
strated by an increase in mortality or
other serious toxicological ﬁndings at the
highest dose, not by a slight reduction in
body weight. No serious toxicological
ﬁndings were reported at the highest
doses for the mouse studies in the RAR.
While some would argue that these high
doses could cause cellular disruption (eg,
regenerative hyperplasia) leading to
cancer, no evidence of this was reported
in any study. Finally, a lack of preneoplas-
tic lesions for a signiﬁcant neoplastic
ﬁnding is insufﬁcient reason to discard the
ﬁnding.
MECHANISTIC INFORMATION
The BfR Addendum dismisses the IARC
WG ﬁnding that ‘there is strong evidence
that glyphosate causes genotoxicity’ by
suggesting that unpublished evidence not
seen by the IARC WG was overwhelm-
ingly negative and that, since the reviewed
studies were not done under guideline
principles, they should get less weight. To
maintain transparency, IARC reviews only
publicly available data. The use of conﬁ-
dential data submitted to the BfR makes it
impossible for any scientist not associated
with BfR to review this conclusion.
Further weakening their interpretation,
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the BfR did not include evidence of
chromosomal damage from exposed
humans or human cells that were high-
lighted in Tables 4.1 and 4.2 of the IARC
Monograph 3
The BfR conﬁrms (p.79) that the
studies evaluated by the IARC WG on
oxidative stress were predominantly posi-
tive but does not agree that this is strong
support for an oxidative stress mechan-
ism. They minimise the signiﬁcance of
these ﬁndings predominantly because of a
lack of positive controls in some studies
and because many of the studies used gly-
phosate formulations and not pure gly-
phosate. In contrast, the WG concluded
that (p.77) ‘Strong evidence exists that
glyphosate, AMPA and glyphosate-based
formulations can induce oxidative stress’.
From a scientiﬁc perspective, these types
of mechanistic studies play a key role in
distinguishing between the effects of mix-
tures, pure substances and metabolites.
Finally, we strongly disagree that data
from studies published in the peer-
reviewed literature should automatically
receive less weight than guideline studies.
Compliance with guidelines and Good
Laboratory Practice does not guarantee
validity and relevance of the study design,
statistical rigour and attention to sources
of bias.25 26 The majority of research after
the initial marketing approval, including
epidemiology studies, will be conducted
in research laboratories using various
models to address speciﬁc issues related to
toxicity, often with no testing guidelines
available. Peer-reviewed and published
ﬁndings have great value in understanding
mechanisms of carcinogenicity and should
be given appropriate weight in an evalu-
ation based on study quality, not just on
compliance with guideline rules.
GENERAL COMMENTS
Science moves forward on careful evalua-
tions of data and a rigorous review of
ﬁndings, interpretations and conclusions.
An important aspect of this process is
transparency and the ability to question or
debate the ﬁndings of others. This ensures
the validity of the results and provides a
strong basis for decisions. Many of the
elements of transparency do not exist for
the RAR.5 For example, citations for
almost all references, even those from the
open scientiﬁc literature, have been
redacted. The ability to objectively evalu-
ate the ﬁndings of a scientiﬁc report
requires a complete list of cited support-
ing evidence. As another example, there
are no authors or contributors listed for
either document, a requirement for publi-
cation in virtually all scientiﬁc journals
where ﬁnancial support, conﬂicts of inter-
est and afﬁliations of authors are fully dis-
closed. This is in direct contrast to the
IARC WG evaluation listing all authors,
all publications and public disclosure of
pertinent conﬂicts of interest prior to the
WG meeting.27
Several guidelines have been devised for
conducting careful evaluation and analysis
of carcinogenicity data, most after con-
sultation with scientists from around the
world. Two of the most widely used
guidelines in Europe are the OECD guid-
ance on the conduct and design of
chronic toxicity and carcinogenicity
studies17 and the European Chemicals
Agency Guidance on Commission
Regulation (EU) No 286/2011;18 both are
cited in the RAR. The methods used for
historical controls and trend analysis are
inconsistent with these guidelines.
Owing to the potential public health
impact of glyphosate, which is an exten-
sively used pesticide, it is essential that all
scientiﬁc evidence relating to its possible
carcinogenicity is publicly accessible and
reviewed transparently in accordance with
established scientiﬁc criteria.
SUMMARY
The IARC WG concluded that glyphosate
is a ‘probable human carcinogen’, putting
it into IARC category 2A due to sufﬁcient
evidence of carcinogenicity in animals,
limited evidence of carcinogenicity in
humans and strong evidence for two car-
cinogenic mechanisms.
▸ The IARC WG found an association
between NHL and glyphosate based
on the available human evidence.
▸ The IARC WG found signiﬁcant car-
cinogenic effects in laboratory animals
for rare kidney tumours and heman-
giosarcoma in two mouse studies and
benign tumours in two rat studies.
▸ The IARC WG concluded that there
was strong evidence of genotoxicity
and oxidative stress for glyphosate,
entirely from publicly available
research, including ﬁndings of DNA
damage in the peripheral blood of
exposed humans.
The RAR concluded5 (Vol. 1, p.160)
that ‘classiﬁcation and labelling for car-
cinogenesis is not warranted’ and ‘glypho-
sate is devoid of genotoxic potential’.
▸ EFSA4 classiﬁed the human evidence
as ‘very limited’ and then dismissed
any association of glyphosate with
cancer without clear explanation or
justiﬁcation.
▸ Ignoring established guidelines cited in
their report, EFSA dismissed evidence
of renal tumours in three mouse
studies, hemangiosarcoma in two
mouse studies and malignant lymph-
oma in two mouse studies. Thus, EFSA
incorrectly discarded all ﬁndings of
glyphosate-induced cancer in animals
as chance occurrences.
▸ EFSA ignored important laboratory
and human mechanistic evidence of
genotoxicity.
▸ EFSA conﬁrmed that glyphosate
induces oxidative stress but then,
having dismissed all other ﬁndings of
possible carcinogenicity, dismissed this
ﬁnding on the grounds that oxidative
stress alone is not sufﬁcient for car-
cinogen labelling.
The most appropriate and scientiﬁcally
based evaluation of the cancers reported
in humans and laboratory animals as well
as supportive mechanistic data is that gly-
phosate is a probable human carcinogen.
On the basis of this conclusion and in the
absence of evidence to the contrary, it is
reasonable to conclude that glyphosate
formulations should also be considered
likely human carcinogens. The CLP
Criteria18 (Table 3.6.1, p.371) allow for a
similar classiﬁcation of Category 1B when
there are ‘studies showing limited evi-
dence of carcinogenicity in humans
together with limited evidence of carcino-
genicity in experimental animals’.
In the RAR, almost no weight is given
to studies from the published literature
and there is an over-reliance on non-
publicly available industry-provided
studies using a limited set of assays that
deﬁne the minimum data necessary for
the marketing of a pesticide. The IARC
WG evaluation of probably carcinogenic
to humans accurately reﬂects the results of
published scientiﬁc literature on glypho-
sate and, on the face of it, unpublished
studies to which EFSA refers.
Most of the authors of this commentary
previously expressed their concerns to
EFSA and others regarding their review of
glyphosate28 to which EFSA has published
a reply.29 This commentary responds to
the EFSA reply.
The views expressed in this editorial are
the opinion of the authors and do not
imply an endorsement or support for
these opinions by any organisations to
which they are afﬁliated.
Author afﬁliations
1Environmental Health Consultant, Thun, Switzerland
2The University of Sydney, Sydney, New South Wales,
Australia
3The University of Auckland, Auckland, New Zealand
4Charité University Medicine Berlin, Berlin, Germany
5Cancer Research Institute, Bratislava, Slovak Republic
6Sorbonne Universités, UPMC Univ Paris 06,
UMR8227, Roscoff, France
Portier CJ, et al. J Epidemiol Community Health August 2016 Vol 70 No 8 743
Commentary
7CesareMaltoni Cancer Research Center, Bentivoglio
(Bologna), Italy
8Institute for Cancer Prevention and Research,
University of Florence, Italy
9University of Illinois at Chicago, Chicago, Illinois, USA
10National Cancer Research Institute, San Martino—IST
Hospital, Genoa, Italy
11University of Hamburg, Hamburg, Germany
12STAMI, National Institute of Occupational Health,
Oslo, Norway
13Sciencecorps, Lexington, Massachusetts, USA
14Instituto de Alta Investigación, Universidad de
Tarapacá, Arica, Chile
15Institute for Health and the Environment, University at
Albany, Rensselaer, New York, USA
16Toxicologist, Maplewood, Minnesota, USA
17National Institute of Public Health, Cuernavaca,
Morelos, Mexico
18Boston University School of Public Health, Boston,
Massachusetts, USA
19Department of Public Health, Clinical and Molecular
Medicine, University of Cagliari, Cagliari, Italy
20Department of Preventive Medicine, Fondazione
IRCCS Ca’ Granda Ospedale Maggiore Policlinico,
Milan, Italy
21Department of Environment and Primary Prevention,
IstitutoSuperiore di Sanità, Rome, Italy
22Environmental Defense Fund, Austin, Texas, USA
23Center for Environmental and Occupational Health,
University of Cape Town, Cape Town, South Africa
24Environmental Health Trust, Jackson Hole, Wyoming,
USA and The Hebrew University Hadassah School of
Medicine, Jerusalem, Israel.
25Dalla Lana School of Public Health, University of
Toronto, Canada
26Department of Environmental and Occupational
Health, Drexel University, Philadelphia, Pennsylvania,
USA
27Brody School of Medicine, East Carolina University,
Greenville, North Carolina, USA
28Department of Epidemiology, Lazio Regional Health
Service, Rome, Italy
29University of Louisville School of Medicine, Louisville,
Kentucky, USA
30School of Public Health, Curtin University, Perth,
Western Australia, Australia
31Department of Environmental Toxicology, The
University of Queensland, Brisbane, Australia
32Department of Population Health Sciences, Virginia
Tech, Blacksburg, Virginia, USA
33Paris Descartes University, France
34Epi.Consult GmbH, Musweiler, Germany
35Danish Cancer Society Research Center, Copenhagen,
Denmark
36University Hospital, Orebra, Sweden
37Biostatistics Branch, Netherlands Cancer Institute,
Amsterdam, The Netherlands
38Faculty of Department of Occupational and
Environmental Health, Peking Univ School of Public
Health, Beijing, China
39National Institute for Environmental Health Sciences,
Research Triangle Park, North Carolina, USA
40University of Florida, Gainesville, Florida, USA
41CWJ Consulting, LLC, Cape Coral, Florida, USA
42Institute of Environment, Health and Societies, Brunel
University London, London, UK
43Division of Biostatistics, German Cancer Research
Center, Heidelberg, Germany
44Institute for Risk Assessment Sciences, Utrecht
University, Utrecht, The Netherlands
45National Council of Scientiﬁc and Technological
Research, National University of La Plata,
Argentina
46Arnhold Institute for Global Health, Icahn School of
Medicine at Mount Sinai, New York, USA
47Department of Pharmacology, Wayne State University
School of Medicine, Detroit, Michigan, USA
48Department of Biosciences, University of Helsinki,
Helsinki, Finland
49Department of Epidemiology, University of Iowa, Iowa
City, Iowa, USA
50Cancer Epidemiology Unit, University of Eastern
Piedmont, Novara, Italy
51Cesare Maltoni Cancer Research Center, Bentivoglio
(Bologna), Italy
52Centre for Biophotonics, Lancaster University, UK
53Department of Prevention, Occupational Health Unit,
National Health Service, Padua, Italy
54Department of Epidemiology Lazio Region, Rome,
Italy
55Occupational and Environmental Epidemiology Unit,
ISPO-Cancer Prevention and Research Institute,
Florence, Italy
56Dalla Lana School of Public Health, University of
Toronto, Canada
57Unit of Cancer Epidemiology, University of Turin and
CPO-Piemonte, Torino, Italy
58Department of Environmental and Occupational
Health Sciences, City University of New York School of
Public Health, USA
59School of Nursing and Public Health, University of
KwaZulu-Natal, Durban, South Africa
60Department of Environmental and Occupational
Health, Milken Institute School of Public Health,
The George Washington University, Washington DC,
USA
61Health and Environment-Department of Prevention,
Local Health Authority-Empoli, Florence, Italy
62Department of Biology and Biotechnology “Charles
Darwin”, Sapienza Rome University, Italy
63Department of Environmental Sciences, School of the
Coast & Environment, Louisiana State University, Baton
Rouge, Los Angeles, USA
64Center for Applied Genetics and Genomic Medicine,
University of Arizona Health Sciences, Tucson, Arizona,
USA
65Iowa Superfund Research Program and the
Interdisciplinary Graduate Program in Human
Toxicology, University of Iowa, Iowa City, Iowa, USA
66Center for Research in Health, Work and Environment
(CISTA), National Autonomous University of Nicaragua
(UNAN-León), León, Nicaragua
67Swiss Tropical and Public Health Institute, Associated
Institute of the University of Basel, Basel, Switzerland
68College of Veterinary Medicine, Mississippi State
University, Mississippi State, USA
69Department of Environmental and Occupational
Health, Florida International University, Miami, Florida,
USA
70Department of Veterinary Integrative Biosciences,
Texas A&M University, College Station, Texas, USA
71Faculty of Medicine, University of São Paulo, São
Paulo, Brazil
72Natural Resources Defense Council and George
Washington University, Washington DC, USA
73Nanosafety Research Centre, Finnish Institute of
Occupational Health, Helsinki, Finland
74Radboud Institute for Health Sciences, Radboud
University Medical Center, Nijmegen, The Netherlands
75Department of Pathology, University of Alberta,
Edmonton, Alberta, Canada
76Department of Environmental Health Sciences, Johns
Hopkins Bloomberg School of Public Health, Baltimore,
Maryland, USA
77School of Public Health, University of California,
Berkeley, California, USA
78Faculty of Medicine, University of New South Wales,
Randwick, New South Wales Australia
79Program on Reproductive Health and the
Environment, University of California, San Francisco,
California, USA
80Istituto di Geosceinze e Georisorse (CNR), Padova,
Italy
81University of Torino, Torino, Italy
82German Cancer Research Center, Heidelberg and
Faculty of Pharmacy, Heidelberg University, Germany
83Fred Hutchinson Cancer Research Center, University
of Washington, Seattle, Washington, USA
84Faculty of Public Health, Kuwait University, Kuwait
City, Kuwait
85Department of Public Health Sciences, Medical
University of South Carolina, Charleston, South
Carolina, USA
86Department of Environmental Epidemiology, Imperial
College London, London, UK
87Department of Research, Cancer Registry of Norway,
Institute of Population-Based Cancer Research, Oslo,
Norway; Department of Community Medicine, Faculty
of Health Sciences, University of Tromsø, The Arctic
University of Norway, Tromsø, Norway; Department of
Medical Epidemiology and Biostatistics, Karolinska
Institutet, Stockholm, Sweden; and Genetic
Epidemiology Group, Folkhälsan Research Center,
Helsinki, Finland.
88Department of Pathology, City of Hope Medical
Center, Duarte, California, USA
89Program on Reproductive Health and the
Environment, University of California, San Francisco,
USA
90Okayama University, Okayama, Japan
91Institute of Nanoproduct Safety Research, Hoseo
University, Asan, The Republic of Korea
92University of Padua, Padova, Italy
93Department of Prevention and Evaluation, Leibniz-
Institute for Prevention Research and Epidemiology,
Bremen, Germany
94College of Pharmacy, University of South Florida,
Tampa, Florida, USA
Contributors All authors to this commentary have
participated in its development and approve the
content. MCB, FF, LF, CWJ, HK, TR, MKR, IR and CS
were all participants in the IARC WG. CJP was an
Invited Specialist in the IARC WG. Many of the
remaining authors have also served on IARC Working
Groups that did not pertain to glyphosate.
Competing interests CJP, MTS and DDW are
providing advice to a US law ﬁrm involved in
glyphosate litigation. CJP also works part-time for the
Environmental Defense Fund on issues not related to
pesticides.
Provenance and peer review Commissioned;
externally peer reviewed.
Open Access This is an Open Access article distributed
in accordance with the Creative Commons Attribution
Non Commercial (CC BY-NC 4.0) license, which permits
others to distribute, remix, adapt, build upon this work
non-commercially, and license their derivative works on
different terms, provided the original work is properly
cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
To cite Portier CJ, Armstrong BK, Baguley BC, et al.
J Epidemiol Community Health 2016;70:741–745.
Published Online First 3 March 2016
J Epidemiol Community Health 2016;70:741–745.
doi:10.1136/jech-2015-207005
744 Portier CJ, et al. J Epidemiol Community Health August 2016 Vol 70 No 8
Commentary
REFERENCES
1 IARC. Preamble to the IARC Monographs. 2006.
http://monographs.iarc.fr/ENG/Preamble/
CurrentPreamble.pdf
2 Guyton KZ, Loomis D, Grosse Y, et al. Carcinogenicity
of tetrachlorvinphos, parathion, malathion, diazinon,
and glyphosate. Lancet Oncol 2015;16:490–1.
3 IARC Working Group. Glyphosate. In: Some
organophosphate insecticides and herbicides: diazinon,
glyphosate, malathion, parathion, and tetrachlorvinphos.
Vol 112. IARC Monogr Prog, 2015:1–92.
4 European Food Safety Authority. Conclusion on the
peer review of the pesticide risk assessment of the
active substance glyphosate. EFSA J 2015;13:4302.
5 European Food Safety Authority. Final Addendum to
the Renewal Assessment Report. 2015. http://
registerofquestions.efsa.europa.eu/roqFrontend/
outputLoader?output=ON-4302
6 De Roos AJ, Blair A, Rusiecki JA, et al. Cancer
incidence among glyphosate-exposed pesticide
applicators in the Agricultural Health Study. Environ
Health Perspect 2005;113:49–54.
7 De Roos AJ, Zahm SH, Cantor KP, et al. Integrative
assessment of multiple pesticides as risk factors for
non-Hodgkin’s lymphoma among men. Occup
Environ Med 2003;60:E11.
8 Weisenburger DD. Pathological classiﬁcation of
non-Hodgkin’s lymphoma for epidemiological studies.
Cancer Res 1992;52(19 Suppl):5456s–62s;
discussion 5462s-5464s.
9 Checkoway H, Pearce N, Kriebel D. Research
methods in occupational epidemiology. 2nd edn.
Monographs in epidemiology and biostatistics.
New York: Oxford University Press, 2004:xiv, 372 p.
10 Rothman KJ, Greenland S, Lash TL. Modern
epidemiology. 3rd edn. Philadelphia: Wolters Kluwer
Health/Lippincott Williams & Wilkins, 2008:x, 758 p.
11 Schinasi L, Leon ME. Non-Hodgkin lymphoma and
occupational exposure to agricultural pesticide
chemical groups and active ingredients: a systematic
review and meta-analysis. Int J Environ Res Public
Health 2014;11:4449–527.
12 EPA. Glyphosate; EPA Reg. # 524–308; mouse
oncogenicity study. 1985. V. Accession No. 251007–
014. Tox review 004370. p.
13 JMPR. FAO plant production and protection paper,
178, 2004—pesticide residues in food—2004. Report
of the Joint Meeting of the FAO Panel of Experts on
Pesticide Residues in Food and the Environment and
WHO the Core Assessment Group; Vol 178. Geneva,
Switzerland: World Health Organization/Food and
Agriculture Organization, 2004:95–169.
14 EPA. Second peer review of Glyphosate. 19911–19.
15 EPA. Glyphosate—EPA Registration No. 524–308–
2-Year Chronic Feeding/Oncogenicity Study in Rats
with Technical Glyphosate, I. William Dykstra.
Toxicology Branch, Editor. 1991. V. MRID 416438–
01 Tox review 008897. p.
16 EPA. Glyphosate; 2-Year Combined Chronic Toxicity/
Carcinogenicity Study in Sprague-Dawley Rats—List
A Pesticide for Reregistration, B. William Dykstra.
Toxicology, Editor. 1991. V. MRID 416438–01. Tox
review 008390. 1–29.
17 OECD. Guidance Document 116 on the Conduct and
Design of Chronic Toxicity and Carcinogenicity Studies,
H.a.S.P. Environment, Editor. Paris: OECD, 2012.
18 European Chemicals Agency. Guidance on the
Application of the CLP Criteria: Guidance to
Regulation (EC) No 1272/2008 on classiﬁcation,
labelling and packaging (CLP) of substances and
mixtures. Helsinki, Finland: European Chemicals
Agency, 2015.
19 NRC Committee to Review the Styrene Assessment in
The National Toxicology Program 12th Report on
Carcinogens. Review of the Styrene Assessment in
the National Toxicology Program 12th Report on
Carcinogens: Workshop Summary; Washington DC:
National Academies Press, 2014.
20 Keenan C, Elmore S, Francke-Carroll S, et al. Best
practices for use of historical control data of
proliferative rodent lesions. Toxicol Pathol
2009;37:679–93.
21 Haseman JK, Boorman GA, Huff J. Value of
historical control data and other issues related
to the evaluation of long-term rodent
carcinogenicity studies. Toxicol Pathol 1997;25:
524–7.
22 Greim H, Gelbke HP, Reuter U, et al. Evaluation of
historical control data in carcinogenicity studies. Hum
Exp Toxicol 2003;22:541–9.
23 Haseman JK, Huff J, Boorman GA. Use of historical
control data in carcinogenicity studies in rodents.
Toxicol Pathol 1984;12:126–35.
24 Giknis M, Clifford C. Spontaneous Neoplastic Lesions
in the CrI:CD-1(ICR)BR Mouse. Charles River
Laboratories; 2000.
25 Myers JP, vom Saal FS, Akingbemi BT, et al. Why
public health agencies cannot depend on good
laboratory practices as a criterion for selecting data:
the case of bisphenol A. Environ Health Perspect
2009;117:309–15.
26 Buonsante VA, Muilerman H, Santos T, et al. Risk
assessment’s insensitive toxicity testing may cause it
to fail. Environ Res 2014;135:139–47.
27 IARC Monograph 112. List of Working Group
Participants. IARC Monogr Eval Carcinog Risks Hum
2015 26 March, 2015 [cited 2015 24 November].
http://monographs.iarc.fr/ENG/Meetings/
vol112-participants.pdf
28 Portier CJ, et al. Open Letter: Review of the
Carcinogenicity of Glyphosate by EFSA and BfR.
2015 [cited 2016 1/18/2016]. http://www.efsa.
europa.eu/sites/default/ﬁles/Prof_Portier_letter.pdf
29 Url B. Response to Open Letter: Review of the
Carcinogenicity of Glyphosate by EFSA and BfR.
2016. 1/13/2016. http://www.efsa.europa.eu/sites/
default/ﬁles/EFSA_response_Prof_Portier.pdf
Portier CJ, et al. J Epidemiol Community Health August 2016 Vol 70 No 8 745
Commentary
European Food Safety Authority (EFSA)
for Research on Cancer (IARC) and the
glyphosate between the International Agency 
Differences in the carcinogenic evaluation of
Zambon, Hajo Zeeb and Shu-Feng Zhou
Weisenburger, Tracey J Woodruff, Takashi Yorifuji, Il Je Yu, Paola 
Vainio, John E Vena, Paolo Vineis, Elisabete Weiderpass, Dennis D
Tateo, Benedetto Terracini, Heinz W Thielmann, David B Thomas, Harri 
Silbergeld, Martyn T Smith, Bernard W Stewart, Patrice Sutton, Fabio
Sass, Kai Savolainen, Paul T J Scheepers, Consolato Sergi, Ellen K 
Röösli, Matt K Ross, Deodutta Roy, Ivan Rusyn, Paulo Saldiva, Jennifer
Kenneth S Ramos, Larry W Robertson, Theresa Rodriguez, Martin 
Melissa J Perry, Maria Grazia Petronio, Roberta Pirastu, Ralph J Portier,
Anthony B Miller, Dario Mirabelli, Franklin E Mirer, Saloshni Naidoo, 
Mandrioli, Francis L Martin, Enzo Merler, Paola Michelozzi, Lucia Miligi,
Dariusz Leszczynski, Charles F Lynch, Corrado Magnani, Daniele 
Kromhout, Marcelo L Larramendy, Philip J Landrigan, Lawrence H Lash,
Jameson, Andreas Kortenkamp, Annette Kopp-Schneider, Hans 
Michael Hauptmann, Wei Huang, James Huff, Margaret O James, C W
Marcel Goldberg, Eberhard Greiser, Johnni Hansen, Lennart Hardell, 
Jonathan H Freedman, Lin Fritschi, Caroline Gaus, Julia M Gohlke,
Demers, Anneclaire J De Roos, Jamie DeWitt, Francesco Forastiere, 
Comba, Elena Craft, Mohamed Aqiel Dalvie, Devra Davis, Paul A
López-Carrillo, Richard Clapp, Pierluigi Cocco, Dario Consonni, Pietro 
Burns, Gloria M Calaf, David O Carpenter, Hillary M Carpenter, Lizbeth
Bosland, Paolo Bruzzi, Lygia Therese Budnik, Merete D Bugge, Kathleen 
CIgor Belyaev, Robert Bellé, Fiorella Belpoggi, Annibale Biggeri, Maarten 
Christopher J Portier, Bruce K Armstrong, Bruce C Baguley, Xaver Baur,
doi: 10.1136/jech-2015-207005
online March 3, 2016
2016 70: 741-745 originally publishedJ Epidemiol Community Health
 http://jech.bmj.com/content/70/8/741
Updated information and services can be found at: 
These include:
References
 http://jech.bmj.com/content/70/8/741#ref-list-1
This article cites 13 articles, 1 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (342)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on April 2, 2018 - Published by http://jech.bmj.com/Downloaded from 
